Heron Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.56 million compared to USD 182.02 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 1.67 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.985 USD | +6.23% | -0.83% | +75.59% |
May. 07 | Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.59% | 423M | |
+29.77% | 49.18B | |
+0.94% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.58% | 26.09B | |
-22.76% | 18.71B | |
+8.49% | 13.26B | |
+32.20% | 12.32B | |
-0.96% | 11.99B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023